Contact Us
Chengguan District, Lanzhou, Gansu, China
© 2025 Jeifer Pharmaceutical, All Right
Reserved.
Glycine came into focus in the mid-1800s, gaining more attention as biochemistry grew. J. P. Mulder isolated it from gelatin, recognizing it as the smallest amino acid nature has put together. Its simple structure—just two carbons, five hydrogens, one oxygen, and two nitrogens—made it easy for chemists to understand yet striking for biologists looking to map life’s most basic processes. As medicine industrialized, demand followed suit. Companies sought to meet the standards of British Pharmacopoeia (BP), European Pharmacopoeia (EP), and United States Pharmacopeia (USP), ensuring lots sold to hospitals would reach the same high purity every time. Watching chemistry labs pivot from rudimentary extracts to precise syntheses, I’ve seen first-hand how regulatory oversight changed things. It went from scattered, unpredictable batches to something that fit right in with global pharmaceutical standards, paving the way for today’s highly regulated raw material markets.
Glycine carries a reputation for reliability. Think of it as a silent helper, found in pills, powders, and injectable solutions. Its role in pharmaceutical manufacturing covers everything from acting as a buffering agent to stabilizing proteins. In nutrient media, researchers rely on glycine for cell culture growth and to support life-saving products we often overlook. Suppliers put out crystals and powders, usually in white to off-white color, which shows the precise refining that pharma-grade processing accomplishes. Picking the right grade matters. BP, EP, and USP standards force factories to run extra purity checks, cutting out trace metals or contaminants. These rules mean a bag marked "pharma grade" isn’t just a label—it’s a promise to doctors, patients, and researchers that nothing dangerous made it past quality control.
Glycine, being the simplest amino acid, lacks side chains that complicate either handling or analysis. At room temperature, it appears as a white, odorless crystalline powder. It dissolves easily in water, stays stable under normal conditions, and has a melting point above 230°C. Such a straight-laced profile makes glycine fit for sterile environments or high-spec applications in IV infusions and injectable drugs. Its molecular weight—75.07 g/mol—and absence of a real aroma have real, practical value in chemical engineering jobs where mixing off-odors or unwanted flavors can ruin batches. In my lab days, measuring its pH was quick and predictable, rarely met with surprises. The absence of tricky byproducts or unstable isomers turns glycine into an ingredient production managers trust.
Every pharma-container label reads like a catalog of compliance. Beyond the glycine content—usually listed at 98.5% to 101.0%—manufacturers publish facts on heavy metals, sulphated ash, loss on drying, chloride, ammonium, and more. Some include a unique lot code, shelf life, storage temperature, and proper closure techniques. Standard labeling ensures every shipment meets regulatory rules across the world. Certificate of Analysis (CoA) data backs up every batch, including HPLC or titration figures for purity, and even microbial limits, which confirm it won’t introduce bacteria into sterile environments. Global rules insist on clear transport conditions—cool, dry, away from sunlight—to keep glycine from clumping or degrading. These labeling practices keep procurement teams and pharmacists confident, reducing errors that could threaten safety or lead to cross-contamination.
Glycine production, on an industrial scale, moved from extraction out of gelatin to chemical synthesis over the years. The most common current method involves reacting chloroacetic acid with ammonia. Factories monitor pH, temperature, and mixing speed to prevent unwanted byproducts. After the main reaction, they neutralize excess acid and wash the end-product many times before crystallization. Refined glycine needs filtration, drying, and grinding. Residual solvents or leftover reactants draw extra scrutiny, especially under pharma-grade standards. I’ve seen technicians run chromatographic tests on samples before they ever leave the factory floor, ensuring no trace contaminants sneak through. This tight control separates pharma-grade glycine from cheaper, technical carpets that can harbor dangerous residues.
Glycine serves as both a starting point and a useful intermediate for other reactions. Its amino and carboxyl groups react cleanly in peptide synthesis, which biochemists exploit to build more complex molecules for research or therapy. Glycine also undergoes N-alkylation or acylation without fuss, making it valuable for developing prodrugs, building imaging agents, or designing new salts. Its ready reactivity lets analytical chemists measure enzyme activities or test new metabolic hypotheses. Modifications like methylation or the attachment of protective groups expand its uses in organic and medicinal chemistry. Its simplicity means results are predictable, less prone to mystery byproducts, and easy for both industry and academia to track.
Glycine answers to many names depending on training or background: Aminoacetic acid, Glycocoll, Glycinum, and NCI-C55843 turn up in regulatory and chemical catalogs. Suppliers may market it under brand-sounding names, but always link back to CAS number 56-40-6 for regulatory clarity. Such a range of synonyms sometimes creates confusion for buyers triaging through international safety data sheets. Consistent referencing by CAS and compliance documentation helps industry avoid mix-ups, especially when crossing borders or shifting between analytical and manufacturing contexts.
Glycine sits squarely inside modern safety guidelines. Acute oral toxicity remains low, making accidental exposure a lesser concern during manufacturing. Those who work with bulk volumes still receive gloves and protective eyewear. Dust from fine crystals can irritate eyes or respiratory tracts, as with many powders. Detailed instructions in safety datasheets outline spill response, storage recommendations, and disposal. Emergency showers and ventilated workstations appear in any plant using the compound in larger batches. Quality control labs check not only for purity but also for microbial and endotoxin contamination, reinforcing safety further up the chain before the material ever touches a patient-facing product.
Glycine finds a home across a dizzying span of medical roles: excipient in IV solutions, stabilizer in protein drugs, component in oral supplements, and even part of special diets for those with metabolic conditions. Diagnostic labs use glycine-based buffers in electrophoresis and immunoassays. Outside medicine, glycine appears in food products, supporting artificial sweeteners and fortification. In veterinary fields, glycine helps in rehydration mixes for animals. The sheer practicality and affordability cuts across research, treatment, and prevention. Demand from global health emergencies—like increased IV therapy during infection outbreaks—puts a spotlight on glycine’s quiet utility.
Ongoing work explores how glycine supplementation can benefit patients with metabolic disorders or psychiatric conditions. Trials probe its role as a neuroprotectant, with early data around ischemic stroke or schizophrenia management. Basic science labs run studies testing glycine’s signaling capabilities in the nervous system, revealing a complexity that belies its size. New inspection technologies, from better chromatography to cleanroom robotics, drive purity even higher. Improved downstream processing reduces unwanted byproducts or costly energy inputs, nudging the industry toward greener operations. The drive to deliver “ultra-pure” batches with ever-stricter microbial standards reflects a continuous upgrade as knowledge and regulation evolve.
Extensive animal and cell-culture studies show a benign profile at levels needed for therapy or supplementation. Large doses do lead to mild gastrointestinal discomfort, but nothing more sinister in properly formulated applications. No chronic toxicity emerged in long-term administration. Regulatory agencies — including the US FDA and European Medicines Agency — classify it as safe for intended pharmaceutical and nutritional use. Special caution only arises in early childhood or special metabolic diseases where glycine accumulation could trigger side effects. Monitoring programs keep tabs on adverse events to catch rare reactions, and adverse event reporting ensures prompt mitigation if safety signals ever show up in larger populations.
Interest in glycine continues as new demand appears in metabolic medicine, peptide-based drugs, and personalized nutrition. With more complex biotherapeutics entering the market, need for high-purity reagents climbs. Automation and AI-driven batch monitoring cut human error, tightening quality to a level rare a decade ago. Interest in climate-friendly production may shift sourcing to biotechnological fermentation, shrinking chemical waste and improving cost profiles. As health care moves towards tailored delivery, glycine’s backbone-like flexibility—structurally and in application—should keep it key in formulation science, research, and clinical use.
Glycine BP EP USP Pharmaceutical Grade turns up in laboratories and manufacturing plants more often than people might guess. This tiny molecule does much more than serve as one of the building blocks of proteins — it plays a hands-on role in the safety and effectiveness of medicines many take every day. Looking back at work carried out with pharmaceutical chemists, I've seen Glycine selected not just for its purity, but because it handles tough tasks in medicine manufacturing that few other compounds can.
Pharma manufacturers often use Glycine to adjust and keep the pH of injectable drugs stable. IV solutions, especially, require serious precision. A wrong pH can cause discomfort—or worse, lead to instability in drugs meant to save lives. This grade of Glycine ensures that injectable solutions stay in the safe pH range longer. Without such stability, drug manufacturers face both safety and regulatory headaches, and patients may not get the treatment they need in time.
Glycine also acts as an active ingredient. Doctors sometimes prescribe Glycine as part of therapies for metabolic disorders. In these treatments, only the purest form meets tight regulatory demands, which is why BP (British Pharmacopoeia), EP (European Pharmacopoeia), and USP (United States Pharmacopeia) grades matter. Contaminants or heavy metals have no place in such critical uses.
Glycine plays its part in oral drugs too. Whether for antacids or amino acid supplements, it finds its way into both tablets and powders. Unlike some chemical additives, Glycine stands out thanks to its safety profile; it doesn’t cause harsh reactions in the stomach and usually doesn’t trigger allergies. I’ve watched quality assurance teams spend days verifying raw material certificates to ensure this level of safety. When a patient swallows a tablet, few realize that such effort went into choosing even one minor compound like Glycine.
Some topical creams, especially wound-healing solutions and hydrogels, rely on Glycine’s compatibility. Its presence supports skin healing, especially in products where purity and gentle impact are both required. In any hospital, staff want to use creams and gels that don’t irritate tender skin. Glycine answers this need with its well-proven record of safety.
Research labs depend on Glycine BP EP USP for buffer preparations, particularly in protein and molecular biology studies. Gel electrophoresis, a bread-and-butter technique for separating proteins, requires a reliable buffer to work well. If the buffer contains impurities, months of research could be lost. As someone who's seen researchers redo experiments due to tainted chemicals, I can’t overstate how much a trusted supply matters.
The demand for pure Glycine doesn’t just come from regulatory paperwork. Patients risk their health each time they take a medication, so there’s little room for shortcuts. Pharmaceutical inspectors and manufacturers collaborate to keep Glycine purity in check. Regular audits, supplier reviews, and updated sourcing methods show how keeping standards high isn’t about ticking boxes; it’s about trust.
Going forward, investment in transparent supply chains and advanced quality testing will cut the risk of contaminated batches. Encouraging local production where possible, with clear traceability from source to finished drug, builds resilience. Everyone wants assurance that the medicines on their pharmacy shelf truly deliver. Glycine BP EP USP may sound technical, but its importance finds a home in real-world health and safety.
I remember my first job in a compounding pharmacy, and glycine came up more than once in discussions with the chemists. Glycine stands out for its purity and versatility—two qualities pharmaceutical teams rely on. Pharma grade glycine, specifically the BP, EP, and USP grades, isn’t just a fancy label. Each grade links to official pharmacopeial standards. Those standards really do matter in the real world, because one slight impurity can cause side effects or, worse, harm vulnerable patients.
From what I’ve seen, the BP (British Pharmacopoeia), EP (European Pharmacopoeia), and USP (United States Pharmacopeia) specifications are not just administrative hurdles. These are safety measures. Each batch needs to meet strict limits on heavy metals, microbial contamination, and residual solvents. I’ve watched QA specialists fire up their lab equipment to re-check new shipments. If you skip these checks, a single oversight could ripple out into dozens of products down the line.
Contamination issues make big headlines, but they also ruin confidence and delay patient care. Pharma grade glycine under these standards meets purity levels of 99% or greater. That’s not a marketing number—analytical techniques, including HPLC and spectroscopy, back it up. The required testing data gives every person down the supply chain—from sourcing teams to clinical researchers—confidence that each dose contains exactly what the final medicine label lists.
Non-pharma or food grades can seem interchangeable on a spreadsheet, but you find the differences in trace analysis and practical use. For instance, a pharmaceutical product designed for IV use can't risk introducing a single microbe or foreign particle. Injectable medicines have zero tolerance for endotoxin contamination, something only pharma grade inputs can manage. Once saw an injectables project get pulled because initial excipient grades didn’t meet final pharmacopeial specs—a financial and reputational headache for everyone involved.
High quality glycine serves a key function in real treatments. In oral and injectable formulations, it acts as a stabilizer or pH buffer. The certainty that comes with pharma grade inputs streamlines R&D and regulatory pathways. I’ve talked to regulatory affairs professionals who would never add anything but BP/EP/USP-compliant glycine to their submissions, knowing that one question from an agency can set progress back by months.
With increasing globalization, medicines cross borders fast. Regulatory agencies—whether it’s the FDA, EMA, or MHRA—honor pharmacopeial certifications. They check Certificates of Analysis, audit supply chains, and look for clean traceability. I’ve watched regulatory teams inspect supplier documentation before finalizing a purchase. If glycine carries BP, EP, or USP certification, that process gets faster and smoother. Without these stamps, pharma companies stare down more scrutiny, longer review periods, and steeper costs to fill in compliance gaps.
Even with the right grade, storage and transport play a crucial role. I’ve seen temperature fluctuations ruin perfectly good batches. Simple steps, like adding environmental monitoring during shipping, can protect expensive stocks. In addition, clear supplier agreements and annual audits reduce the persistent risk of cross-contamination or adulteration. Choosing pharma grade excipients like glycine removes one more worry from a crowded regulatory landscape, letting drug makers focus on real innovation rather than avoidable recalls or health scares. Reliable excipients anchor safer, more resilient supply chains, which leads to better outcomes for patients everywhere.
In pharmaceutical manufacturing, every step matters. Packaging ranks among the most practical concerns in the business. For glycine made to BP, EP, and USP pharma-grade standards, the way it’s packed can shape its safety, stability, and usability from the warehouse to the lab. Most people outside the industry might imagine simple bottles or pouches, but the variations in pharmaceutical packaging often carry more weight than what’s on the label. Over the years, I have seen how a smart packaging decision can trim waste, cut costs, and even prevent contamination—the kinds of real-world problems that everyone working with glycine knows all too well.
Bags and drums set the standard for glycine’s journey through the pharma world. Polyethylene-lined fiber drums, usually sized between 25 to 50 kilograms, allow safe movement of high-purity glycine without direct exposure to the elements. High-density polyethylene bags, typically double-layered and sealed tightly, offer strong protection against moisture and cross-contamination. If a facility in Mumbai needs a few tons per quarter, palletized drums offer efficiency, keeping the product in a stable state during shipping and storage.
Bulk bags, or so-called flexible intermediate bulk containers (FIBCs), come into play for even larger-scale needs. These hold 500 kilograms or more and allow quick filling and emptying in automated systems. For anyone running a high-output factory, that speed translates to fewer bottlenecks and fewer opportunities for handling mistakes. The trade-off with bulk options remains clear: they demand robust traceability and well-defined operating procedures to keep the powder uncontaminated, especially for pharma uses.
On the lab side, resealable HDPE bottles, ranging from 500 grams up to 5 kilograms, are common. These containers block out light and moisture and allow researchers or pharmacists to open and reseal them several times without risking quality. During my time working in a clinical lab, small packs often helped keep batches fresh, reduced spills, and eased daily inventory checks. No one wants to open a multi-kilo drum just to weigh out a few grams at a time.
Glass containers see less use in today’s supply chains. Even so, they sometimes surface for extremely moisture-sensitive tasks, as glass stands up well to long-term storage. Tins lined with food-grade material offer another niche solution for environments where product purity means everything. Each type of pack must meet tight regulatory standards set by global agencies. Regulatory compliance means tamper-evident seals, batch traceability, and the right labeling, all documented through ongoing audit trails. Manufacturers need to guarantee that no matter the pack size, content identity and purity never fall into doubt.
Waste produced by single-use plastics and oversized packaging remains a core problem. Forward-thinking suppliers have started using recyclable liners, returnable drums, and even biodegradable pouches. Several global players now run drum-return schemes, cutting landfill waste and slashing shipping costs. In recent years, I have seen interest grow around paper-based packaging reinforced with polymer barriers, aiming to balance sustainability and safety. Simple changes like this can help change long-standing industry habits. Companies that adapt see less environmental liability on their balance sheets and good faith from more eco-conscious clients.
Choosing the best packaging for glycine pharma supplies is not just a technical issue. It calls for a mix of safety, practicality, and responsibility. As regulatory pressures grow and new therapies develop, suppliers and buyers should stay ready to rethink old standards in packaging to suit modern needs—both on the lab bench and beyond.
Glycine, a basic amino acid, does more than sit on a lab shelf. Drug manufacturers, supplement makers, and researchers lean heavily on its purity when formulating medicines and other products that have direct impact on human health. British Pharmacopoeia (BP), European Pharmacopoeia (EP), and United States Pharmacopeia (USP) each outline purity specifications tailored for the toughest pharmaceutical applications.
These pharmacopeias demand that glycine gets produced and checked against strict chemical and physical criteria. For instance, the glycine content must typically measure at least 98.5% to 101.5% on the dried basis. This tight range guarantees that batches don’t stray too far from the level needed for safe and effective use in products that go in or on the human body.
Every pharmacopoeia shares a common goal—keeping toxic contaminants out of medicines. Guidelines limit impurities like heavy metals, chlorides, sulfates, ammonium, and loss on drying. Heavy metals, often capped at 10 ppm (parts per million) or less, present a clear risk if not controlled. Even slight excesses of contaminants like lead or arsenic are not tolerated, because exposure over time can lead to chronic health issues or, in worst cases, acute poisoning. It’s not just about ticking boxes; it's about protecting patients.
Loss on drying gives insight into the amount of moisture left in the glycine powder. Too much water can breed bacteria or degrade drug formulations, so specs routinely limit water above 0.2%. Sulfate and chloride limits keep the product stable and compatible with other ingredients in a mixture. Ammonium levels, checked through color reactions or instrumental tests, need to stay far below thresholds that would affect taste, odor, or, worse, safety.
Purity tests draw from the sciences of chemistry and biology, not just paperwork. Identity gets checked with infrared spectrometry, melting point, and specific optical rotation. Darwin’s idea of adaptation applies; even small changes in purity or impurities can alter how something works in a body or a lab. Glycine used in pharmaceuticals can't fudge corners, since it touches health at its core.
I once saw a nutritional supplement facility halt a big batch because glycine turned up with traces of residual solvents above USP limits. No one likes delays, but every staff member understood the gravity. Releasing substandard material could trigger recalls, hurt consumers, or erode hard-won trust. Facilities who work with pharmaceutical-grade ingredients know that proper supply chain audits, validated laboratory methods, and rigorous certifications from reliable labs aren’t optional. These steps set the foundation for safe and consistent finished products.
Many people outside the industry don’t realize how demanding these standards are. It’s much more than paperwork for compliance officers. Glycine passing BP, EP, or USP means the manufacturer stood up to outside scrutiny and ran the gauntlet of analytical chemistry. This boosts confidence not only for regulators but also for pharmacists, physicians, and patients, who rely on predictable performance from every dose or tablet.
Manufacturers who cut corners or skip testing compromise more than a product; they take risks with health and reputation. Strict specification adoption, paired with open reporting and transparent supply chains, can lift the sector and protect people day in, day out.
Many folks in the pharmaceutical world ask if Glycine labeled as BP EP USP Pharma Grade actually lines up with the strict standards set by global pharmacopeias. I remember working on a project where one inconsistent ingredient led to an expensive product recall and lost faith among clients. Scientists, manufacturers, and consumers all look for something dependable—I learned that lesson the hard way. The only way people feel safe is when every batch gets checked against known standards.
The British Pharmacopoeia (BP), European Pharmacopoeia (EP), and United States Pharmacopeia (USP) each publish detailed requirements that ingredients must meet before moving into medicines or supplements. These aren’t loose checklists. For Glycine, these books lay down purity limits, set acceptable identity tests, specify how much moisture and heavy metal content shows up, and put boundaries on things like endotoxin and microbial burden.
For example, USP Glycine must pass identity checks using infrared absorption, melting point, and chemical reaction tests. The content, usually not less than 98.5% and not more than 101.5%, gets measured by titration. BP and EP list similar markers, but sometimes methods differ. It all boils down to strict editing: no room for off-spec impurities, years of research packed into one slim monograph.
I’ve met buyers who see “Pharma Grade” and assume that settles things. That phrase should mean Glycine has the documentation and quality testing to back it up—Batch-to-batch Certificates of Analysis, validated manufacturing processes, and full traceability back to the raw materials. It’s not just about sticking a label on a drum. A supplier worth working with welcomes outside audits, shares their production data, and understands why regulators care about safety.
Documentation carries weight. I’ve sat through supplier audits where teams review not just the finished batch record, but the minute calibration logs for balances. They ask if the water used in synthesis meets pharmacopeia chapter standards. Real “Pharma Grade” suppliers can defend their product line by line.
Some Glycine marketed for lab use or food processing doesn’t go through all the checks required for BP, EP, or USP listing. These powders may still look the same on paper, but one step missed in purification or one outdated testing method, and the product risks failing an audit. I’ve heard from quality managers who caught out-of-spec amino acid profiles because a vendor skimped on full-round testing. The difference may seem minor until that same impurity builds up in a patient’s dose. That’s a risk nobody wants to defend in court.
Companies often want the reassurance that every raw material meets not just a grade, but the exact version of each pharmacopeia required by their target markets. The global supply chain joined with country-specific test protocols means each batch matters, every time.
Real compliance demands active checking. I’ve seen the difference made by using suppliers certified to ISO 9001 or GMP, and requiring fresh Certificates of Analysis matched against the product’s shipping label. Pharmaceutical buyers now often send their own samples for independent lab confirmation, especially if the ingredient gets made or shipped from overseas. Setting up regular audits and being present at the plant makes sure shortcuts don’t get taken.
Laws and best practices will keep pushing this bar higher, but the basics always hold: if Glycine BP EP USP Pharma Grade doesn’t meet monograph standards, it can’t claim that grade. Patients depend on ingredients that live up to the letter of these books. For everyone who works in the field, that responsibility can’t just get checked off a list—each step matters.
| Names | |
| Preferred IUPAC name | 2-aminoacetic acid |
| Other names |
Aminoacetic acid Glycocoll Glycinum Pharmaceutical Glycine 2-Aminoacetic acid |
| Pronunciation | /ˈɡlaɪˌsiːn biː piː iː piː juː ɛs piː ˈfɑːrmə ɡreɪd/ |
| Identifiers | |
| CAS Number | 56-40-6 |
| 3D model (JSmol) | `C(C(=O)O)N` |
| Beilstein Reference | 17104 |
| ChEBI | CHEBI:15428 |
| ChEMBL | CHEMBL123 |
| ChemSpider | 710 |
| DrugBank | DB00145 |
| ECHA InfoCard | 03b3df6c-513d-40fb-88c9-6126a8136789 |
| EC Number | 40-140-0 |
| Gmelin Reference | 1263 |
| KEGG | C00037 |
| MeSH | D02.705.400.400.400, D12.125.465.458.400 |
| PubChem CID | 750 |
| RTECS number | MS7700000 |
| UNII | K48IDO8K6W |
| UN number | UN2811 |
| CompTox Dashboard (EPA) | DTXSID7020982 |
| Properties | |
| Chemical formula | C2H5NO2 |
| Molar mass | 75.07 g/mol |
| Appearance | White crystalline powder |
| Odor | Odorless |
| Density | 0.9 g/cm³ |
| Solubility in water | Soluble in water |
| log P | -3.21 |
| Acidity (pKa) | 2.35 |
| Basicity (pKb) | 9.60 |
| Magnetic susceptibility (χ) | Diamagnetic |
| Viscosity | 1% w/v aqueous solution: 1.0 mPa·s |
| Dipole moment | 1.25 D |
| Thermochemistry | |
| Std molar entropy (S⦵298) | 101 J·mol⁻¹·K⁻¹ |
| Std enthalpy of formation (ΔfH⦵298) | -528.2 kJ/mol |
| Std enthalpy of combustion (ΔcH⦵298) | -968.6 kJ/mol |
| Pharmacology | |
| ATC code | A16AA01 |
| Hazards | |
| Main hazards | May cause eye, skin, and respiratory tract irritation. |
| GHS labelling | GHS labelling: Not classified as hazardous according to GHS. |
| Pictograms | Acute Tox. 4, Eye Irrit. 2B |
| Signal word | Warning |
| Hazard statements | Hazard statements: Not a hazardous substance or mixture according to Regulation (EC) No. 1272/2008. |
| Precautionary statements | Precautionary Statements: Store in a tightly closed container. Store in a cool, dry, well-ventilated area away from incompatible substances. Avoid contact with eyes, skin, and clothing. Wash thoroughly after handling. |
| NFPA 704 (fire diamond) | 2-1-0 |
| Flash point | > 233°C |
| Autoignition temperature | 315°C |
| Explosive limits | Explosive limits: Not explosive |
| LD50 (median dose) | LD50 (oral, rat) 7930 mg/kg |
| PEL (Permissible) | Not established |
| REL (Recommended) | 0.25 g/kg |
| IDLH (Immediate danger) | Not established |
| Related compounds | |
| Related compounds |
Ammonia Glycylglycine Glycylglycylglycine Sarcosine Aminoacetic acid Glycine methyl ester |
Chengguan District, Lanzhou, Gansu, China
